Development and validation of the WebAd-Q Questionnaire to monitor adherence to HIV therapy

Authors

  • Felipe Campos Vale Universidade de São Paulo. Faculdade de Medicina. Programa de Pós-Graduação em Medicina Preventiva
  • Ernani Tiaraju de Santa-Helena Universidade Regional de Blumenau. Departamento de Medicina. Programa de Pós-Graduação em Saúde Coletiva
  • Maria Altenfelder Santos Universidade de São Paulo. Faculdade de Medicina. Programa de Pós-Graduação em Medicina Preventiva
  • Wania Maria do Espirito Santo Carvalho Universidade de São Paulo. Faculdade de Medicina. Programa de Pós-Graduação em Medicina Preventiva
  • Paulo Rossi Menezes Universidade de São Paulo. Faculdade de Medicina
  • Caritas Relva Basso Universidade de São Paulo. Faculdade de Medicina. Programa de Pós-Graduação em Medicina Preventiva
  • Mariliza Henrique Silva Centro de Referência e Treinamento em DST e Aids do Estado de São Paulo
  • Ana Maroso Alves Universidade de São Paulo. Faculdade de Medicina. Programa de Pós-Graduação em Medicina Preventiva
  • Maria Ines Battistella Nemes Universidade de São Paulo. Faculdade de Medicina

DOI:

https://doi.org/10.11606/S1518-8787.2018052000337

Keywords:

Anti-HIV Agents, supply & distribution. HIV Infections, drug therapy. Medication Adherence. Surveys and Questionnaires, utilization. Validation Studies.

Abstract

OBJECTIVE: To present the development and validation of the WebAd-Q Questionnaire, a self-report instrument to monitor adherence to antiretroviral therapy in HIV/AIDS centers in Brazil. METHODS: The WebAd-Q is an electronic questionnaire that has three questions about the use of antiretrovirals in the last week. It was constructed from interviews and focus groups with 38 patients. Its validity was tested in a study with a sample of 90 adult patients on antiretroviral therapy for at least three months. We used electronic monitoring bottles, pill counting, and self-report interview to compare adherence. The WebAd-Q was answered on the sixtieth day, twice, with at least one hour of interval. The viral load of the patients was obtained from the service records. We have analyzed the agreement between the answers to the WebAd-Q, the associations, and the correlations with viral load and performance compared to other measures of adherence. RESULTS: Among the invited patients, 74 (82.2%) answered the WebAd-Q. No difficulties were reported to answer the questionnaire. The average answer time was 5 min 47 sec. The set of three questions of the WebAd-Q obtained agreement of 89.8%, with Kappa of 0.77 (95%CI 0.61–0.94). The non-adherence answers of the WebAd-Q were associated with detectable viral load. We obtained moderate viral load correlations with the non-adherence scale according to the WebAd-Q. For the three questions of the WebAd-Q, patients with non-adherence answers were also reported as less adherent according to the other measures of adherence. CONCLUSIONS: The WebAd-Q answered all the issues considered relevant in the validation of questionnaires, was well understood by patients, was associated with viral load, and obtained good agreement and good performance compared to the other measures. The feasibility analysis of its implementation still depends on a national study on its applicability.

Published

2018-05-22

Issue

Section

Original Articles

How to Cite

Vale, F. C., Santa-Helena, E. T. de, Santos, M. A., Carvalho, W. M. do E. S., Menezes, P. R., Basso, C. R., Silva, M. H., Alves, A. M., & Nemes, M. I. B. (2018). Development and validation of the WebAd-Q Questionnaire to monitor adherence to HIV therapy. Revista De Saúde Pública, 52, 62. https://doi.org/10.11606/S1518-8787.2018052000337